Cynata Therapeutics (CYYNF) Upgraded by Zacks Investment Research to “Hold”

Zacks Investment Research upgraded shares of Cynata Therapeutics (OTCMKTS:CYYNF) from a sell rating to a hold rating in a research report sent to investors on Monday morning, reports.

According to Zacks, “Cynata Therapeutics Ltd is a stem cell and regenerative medicine company. It is developing a therapeutic stem cell platform Cymerus(TM), a mesenchymal stem cell technology for human therapeutic use. Cynata Therapeutics Ltd is based in Armadale, Australia. “

Shares of CYYNF opened at $0.81 on Monday. Cynata Therapeutics has a fifty-two week low of $0.75 and a fifty-two week high of $1.12.

About Cynata Therapeutics

Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease.

Featured Story: What is the Quick Ratio?

Get a free copy of the Zacks research report on Cynata Therapeutics (CYYNF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cynata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cynata Therapeutics and related companies with's FREE daily email newsletter.